Glenmark Pharma: From Licensing Windfall to All-Time Highs

1. Major Corporate Developments Global licensing deal: IGI Therapeutics SA, a wholly-owned arm of Glenmark Pharma, inked an exclusive agreement with AbbVie for its trispecific antibody candidate ISB 2001 targeting cancer and autoimmune disorders. Glenmark will receive $700 million upfront Up to $1.225 billion in milestone payments. Immuno-oncology launch: On June 24, Glenmark introduced Tevimbra—a lung cancer treatment developed by BeiGene—in India, marking its first foray into immune-oncology domestically. This catalyst helped lift the stock 12% in 12 trading days and 37% over two months. 2. Stock Performance Highlights All-time high: Shares spiked to ₹1,886.40 intraday on July 10, reflecting bullish sentiment on the back of Tevimbra’s launch. Recent pullback: As of July 9, Glenmark Pharma traded at ₹1,793.30, down 2.03% and ranking among the top losers on the Nifty Midcap 150 that session. Trading band (July 10 session): Day’s low – ₹1,813.10 Day’s high – ₹1,920.00 52-week range – ₹1,275.50 to ₹1,920.00. 3. Analyst Views Choice Equity Broking anticipates a rebound driven by: A robust respiratory and injectable pipeline 10–12% revenue growth guidance for FY26 Margin uplift from enhanced manufacturing at IGI SA. 4. Upcoming Triggers & Related Themes USFDA Monroe facility inspection: Glenmark received a Form 483 with procedural observations; resolution progress may impact sentiment. Q1 FY26 results: Watch domestic formulations recovery and EU generics performance for fresh stock catalysts. Global pharma context: Potential US tariffs on imports and evolving immuno-oncology landscape could sway valuations.